9PL Stock Chart & Stats
€0.01
>-€0.01(-9.09%)
At close: 4:00 PM EDT
€0.01
>-€0.01(-9.09%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.04M
Enterprise Value€6.14
Total Cash (Recent Filing)€895.00K
Total Debt (Recent Filing)€146.00K
Price to Earnings (P/E)―
Beta11.89
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€54.38K
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendAccelerating revenue growth indicates improving product adoption and market penetration for GENinCode's tests. Sustained top-line expansion supports scale benefits, helps absorb fixed R&D and lab costs, and provides a foundation for margin improvement and eventual profitability if growth continues.
Improving Gross MarginA roughly 50% gross margin shows strengthening unit economics in core genomic testing. Better margins increase the portion of revenue available to cover SG&A and R&D, improving the path to sustainable operating leverage as volumes rise and enabling more durable profitability when scale is achieved.
Focused Genomics/Dx BusinessA clear focus on genomic diagnostics places the company in a structurally growing segment (clinical genetic testing and personalized medicine). Specialization supports defensible product expertise, long-term clinical relationships with labs and clinicians, and recurring demand as genomic testing becomes standard care.
Bears Say
Large Persistent LossesVery large and persistent operating losses indicate the business is not yet near break-even, limiting retained earnings and forcing reliance on external capital. Continued deep losses undermine long-term viability if revenue growth or margin gains do not materially accelerate.
Chronic Cash BurnConsistent negative operating and free cash flow means the company cannot self-fund growth or working capital. Ongoing burn increases dependence on equity or debt raises, diluting shareholders or raising financing costs and constraining strategic flexibility over the medium term.
Weakened Equity / Rising LeverageA sharp drop in equity and a higher debt-to-equity ratio materially reduce financial resilience. Reduced buffer increases insolvency risk if losses persist, limits borrowing capacity, and raises the likelihood of dilutive financing or constrained investment in commercialization and R&D.
GENinCode UK Ltd. News
9PL FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest stock price was <€0.01 and its highest was €0.08 in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is €7.04M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 56 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -22.857%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in DE:9PL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.